Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05676476 · ClinicalTrials.gov registry record · NA
The ACHIEVE Trial: Achieving Longer Gestation in Preeclampsia Via Antihypertensive Therapy.
A NA study of Preeclampsia and Gestational Hypertension, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- NA
- Development phase
- 132
- Enrollment target
- 2
- Study locations
NCT05676476: Recruiting NA study of Preeclampsia and Gestational Hypertension, sponsored by University of Alabama at Birmingham.
NCT05676476 is a NA study of Preeclampsia and Gestational Hypertension that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 132 participants, below the 1,123-participant average among 48 other Preeclampsia trials with a reported enrollment target (88% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05676476, a NA study of Preeclampsia and Gestational Hypertension, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- NA
- Development phase
- 132 participants
- Enrollment target
- 2
- Study locations
Study Summary
The Achieve Trial is a randomized clinical trial to test whether lowering blood pressure to less than 140/90 mmHg in women with hypertensive disorders of pregnancy will prolong pregnancy.
Primary Outcome
Duration of prolongation of pregnancy
Conditions Studied
Interventions
- DRUG Antihypertensive treatment
Study Locations (2)
Alabama
- University of Alabama at Birmingham - Birmingham
Louisiana
- Oschner - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2023-02-14 |
| Est. Completion | 2027-06 |
| Phase | NA |
What NCT05676476 shows while recruiting
NCT05676476 is an interventional study that assigns participants to a tested intervention. The registered 132 participants enrollment target is mid-sized for trials with a published cap, below the 1,123-participant average among 48 other Preeclampsia trials with a reported enrollment target (88% lower).
The record links to 3 conditions, with Preeclampsia appearing as the primary indexed condition, and to 1 intervention - of which Antihypertensive treatment is the first listed.
NCT05676476 reports a single indexed study location in Alabama, Louisiana.
Frequently Asked Questions
What is clinical trial NCT05676476 about?
NCT05676476 is a clinical study titled "The ACHIEVE Trial: Achieving Longer Gestation in Preeclampsia Via Antihypertensive Therapy.". The Achieve Trial is a randomized clinical trial to test whether lowering blood pressure to less than 140/90 mmHg in women with hypertensive disorders of pregnancy will prolong pregnancy.
What is the current status of trial NCT05676476?
This trial is currently recruiting. It is a NA study. The enrollment target is 132 participants. The study started on 2023-02-14. Estimated completion is 2027-06.
What conditions does trial NCT05676476 study?
This clinical trial studies the following conditions: Preeclampsia, Gestational Hypertension, Hypertensive Disorder of Pregnancy.
What interventions are being tested in trial NCT05676476?
The interventions under investigation include: Antihypertensive treatment (DRUG).
Who is sponsoring clinical trial NCT05676476?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05676476 being conducted?
This trial has 2 study locations across Alabama, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Preeclampsia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05676476's enrollment target sits among peer trials
132 25th of 48 higher than 24 of 48 other Preeclampsia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Preeclampsia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial
RECRUITING · NA
-
Optimizing Cardiovascular Preventive Care for Women Following Hypertensive Disorders of Pregnancy
RECRUITING · NA
-
Preventing Obstetric Complications With Dietary Intervention
RECRUITING · NA
-
Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy
RECRUITING · NA
-
Evaluating the Effectiveness of a Food is Medicine Community Health Worker Program for Pregnant Women
RECRUITING · NA
-
Physical Activity to Mitigate PreEclampsia Risk
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01766297 · 132 participants · Phase 2
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- NCT04002947 · 132 participants · Phase 2
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
- NCT04128189 · 132 participants · Phase 3
Shingrix in Renal Transplant Recipients
- NCT04199780 · 132 participants · NA
Effects of tDCS Combined With CBI on Postsurgical Pain
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI